Treatment-resistant depression and mortality after acute coronary syndrome.
Depression is a risk factor for morbidity and mortality in patients with coronary heart disease, especially following acute coronary syndrome. Evidence from recent clinical trials suggests that treatment-resistant depression may be associated with a particularly high risk of mortality or cardiac morbidity in patients following acute coronary syndrome. This article reviews this evidence and considers possible explanations for this relationship. Directions for future research are also considered, with particular emphasis on efforts to elucidate the underlying mechanisms and to develop more efficacious treatments for depression in patients with coronary heart disease.
Carney
Robert M
RM
Behavioral Medicine Center, 4320 Forest Park Blvd. Suite 301, St. Louis, MO 63108, USA. carneyr@bmc.wustl.edu
Freedland
Kenneth E
KE
D054058:Acute Coronary Syndrome / Q000401:mortality* / Q000523:psychology*; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016642:Bupropion / Q000009:adverse effects / Q000627:therapeutic use; D015283:Citalopram / Q000009:adverse effects / Q000627:therapeutic use; D015928:Cognitive Behavioral Therapy; D003131:Combined Modality Therapy; D015897:Comorbidity; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D009203:Myocardial Infarction / Q000401:mortality / Q000523:psychology; D010555:Personality Inventory / Q000706:statistics & numerical data; D011594:Psychometrics; D016032:Randomized Controlled Trials as Topic; D055502:Secondary Prevention; D015996:Survival Rate
D000928:Antidepressive Agents; D016642:Bupropion; D015283:Citalopram